# A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer

> **NCT02737787** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 11 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube
- Primary Peritoneal Cancer
- Recurrent Ovarian Cancer

## Interventions

- **BIOLOGICAL:** WT1 Vaccine
- **DRUG:** Nivolumab
- **BIOLOGICAL:** NY-ESO-1 Vaccine

## Key facts

- **NCT ID:** NCT02737787
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2023-04-06
- **Final completion:** 2023-04-06
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2023-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02737787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02737787, "A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02737787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*